NCT06063109View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

October 9, 2023

Primary Completion Date

November 9, 2023

Study Completion Date

November 9, 2023

Conditions
HypertensionDiabetes Mellitus, Type 2
Interventions
DRUG

THP-00101 (Dapagliflozin) 10mg

Dapagliflozin 10mg Tablet / 5 days in period 1 and period 2 will be given to Arm A Dapagliflozin 10mg Tablet / 5 days in period 2 will be given to Arm B

DRUG

THP-00102 (Telmisartan) 80mg

Telmisartan 80mg Tablet / 5 days in period 1 and period 2 will be given to Arm B Telmisartan 80mg Tablet / 5 days in period 2 will be given to Arm A

Trial Locations (1)

08779

H Plus Yangji Hospital, Seoul

All Listed Sponsors
lead

THPharm Corp.

INDUSTRY

NCT06063109 - A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin. | Biotech Hunter | Biotech Hunter